Founded in December 2012, Swiss Medendi SA developed a proprietary technology for the intravenous (IV) administration of vesicant and irritant drugs. This technology permits a safe chemotherapy infusion via peripheral venous access devices, therefore it protects the patient’s blood vessels from chemical phlebitis and increases the patient’s quality of life. This technology further creates significant cost saving to hospitals and other medical providers. The Swiss Medendi solution offers the safest and most cost effective means for IV infusion of vesicant and irritant drugs minimizing adverse side effects, risks and injuries. Further it results in providing better treatment to the patient by eliminating unnecessary procedures, such as placement of central line (CL) supporting catheter reducing initiatives when the risks exceed their benefits.